SG11202012768XA - Combination therapy using a peptide - Google Patents

Combination therapy using a peptide

Info

Publication number
SG11202012768XA
SG11202012768XA SG11202012768XA SG11202012768XA SG11202012768XA SG 11202012768X A SG11202012768X A SG 11202012768XA SG 11202012768X A SG11202012768X A SG 11202012768XA SG 11202012768X A SG11202012768X A SG 11202012768XA SG 11202012768X A SG11202012768X A SG 11202012768XA
Authority
SG
Singapore
Prior art keywords
peptide
combination therapy
therapy
combination
Prior art date
Application number
SG11202012768XA
Inventor
Lars Prestegarden
Original Assignee
Cytovation As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytovation As filed Critical Cytovation As
Publication of SG11202012768XA publication Critical patent/SG11202012768XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202012768XA 2018-06-19 2019-06-19 Combination therapy using a peptide SG11202012768XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1810058.6A GB201810058D0 (en) 2018-06-19 2018-06-19 Combination therapy using a peptide
PCT/EP2019/066295 WO2019243471A1 (en) 2018-06-19 2019-06-19 Combination therapy using a peptide

Publications (1)

Publication Number Publication Date
SG11202012768XA true SG11202012768XA (en) 2021-01-28

Family

ID=63042825

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012768XA SG11202012768XA (en) 2018-06-19 2019-06-19 Combination therapy using a peptide

Country Status (14)

Country Link
US (1) US20210154268A1 (en)
EP (1) EP3810279B1 (en)
JP (1) JP7525408B2 (en)
KR (1) KR20210022669A (en)
CN (1) CN112566699B (en)
AU (1) AU2019291079A1 (en)
CA (1) CA3103905A1 (en)
DK (1) DK3810279T5 (en)
ES (1) ES2960783T3 (en)
GB (1) GB201810058D0 (en)
IL (1) IL279461A (en)
PL (1) PL3810279T3 (en)
SG (1) SG11202012768XA (en)
WO (1) WO2019243471A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7173993B2 (en) 2017-05-19 2022-11-17 ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド A novel monoclonal antibody against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
GB202000167D0 (en) 2020-01-07 2020-02-19 Cytovation As Composition for treatment of neoplastic lesions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201001602D0 (en) 2010-02-01 2010-03-17 Cytovation As Oligopeptidic compounds and uses therof
RU2016122957A (en) 2013-11-11 2017-12-19 Армо Байосайенсиз, Инк. Methods of using interleukin-10 for the treatment of diseases and disorders
MX2017016931A (en) * 2015-06-24 2018-09-26 Immodulon Therapeutics Ltd A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy.
AU2017234192B2 (en) 2016-03-16 2024-04-04 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine

Also Published As

Publication number Publication date
KR20210022669A (en) 2021-03-03
EP3810279B1 (en) 2023-09-13
ES2960783T3 (en) 2024-03-06
PL3810279T3 (en) 2024-02-26
CN112566699B (en) 2024-07-05
AU2019291079A1 (en) 2021-01-28
WO2019243471A1 (en) 2019-12-26
CA3103905A1 (en) 2019-12-26
IL279461A (en) 2021-01-31
JP7525408B2 (en) 2024-07-30
GB201810058D0 (en) 2018-08-08
DK3810279T5 (en) 2024-08-19
CN112566699A (en) 2021-03-26
EP3810279A1 (en) 2021-04-28
JP2021527677A (en) 2021-10-14
DK3810279T3 (en) 2023-10-23
US20210154268A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
IL277336A (en) Combination therapy
GB201804255D0 (en) Macrophage-based therapy
GB201819853D0 (en) Therapy
GB201900702D0 (en) Therapy
IL280968A (en) Combination therapy
IL279908A (en) Combination therapy
IL279461A (en) Combination therapy using a peptide
IL285144A (en) Therapeutic peptides
IL290520A (en) Therapeutic peptides
IL284006A (en) Mitochondria-targeting peptides
IL280729A (en) Combination therapy
GB201817385D0 (en) Therapy
GB201814036D0 (en) New therapy
GB201919036D0 (en) Therapy
GB201916983D0 (en) Therapy
GB201914848D0 (en) Therapy
GB201820895D0 (en) Therapy
GB201913785D0 (en) Therapy
GB201913797D0 (en) Therapy
GB201912524D0 (en) Therapy
GB201911948D0 (en) Therapy
GB201911064D0 (en) Therapy
IL268046A (en) Peptides for therapy
GB201814038D0 (en) Ilven therapy
GB201807147D0 (en) Therapeutic combination